StockMarketWire.com - Redx announced that Jason Baker and Miles Needham of FRP Advisory, joint administrators of the company and of its subsidiary, Redx Oncology, entered an unconditional agreement for the disposal to Loxo Oncology of certain patents, intellectual property, contracts for product manufacture and physical materials relating to Redx's BTK inhibitor drug development program for $40m. Story provided by StockMarketWire.com